Regeneron Pharmaceuticals
REGN
904 hedge funds and large institutions have $43.6B invested in Regeneron Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 142 funds opening new positions, 374 increasing their positions, 281 reducing their positions, and 135 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 374 | Existing positions reduced: 281
5% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 135
0% less funds holding
Funds holding: 907 → 904 (-3)
1.89% less ownership
Funds ownership: 88.09% → 86.21% (-1.9%)
15% less capital invested
Capital invested by funds: $51.6B → $43.6B (-$7.93B)
18% less funds holding in top 10
Funds holding in top 10: 17 → 14 (-3)
21% less call options, than puts
Call options by funds: $1.02B | Put options by funds: $1.29B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$280M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$244M |
| 3 |
JP Morgan Chase
New York
|
+$211M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$163M |
| 5 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
+$120M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$668M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$479M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$428M |
| 4 |
Goldman Sachs
New York
|
-$163M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$161M |
REGN Hedge Fund Activity: Q4 2020 in Review
904 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2020, worth a combined $43.6B — down 15% from $51.6B a quarter earlier.
Buyers outnumbered sellers: 142 funds opened new REGN positions and 135 closed out — a net gain of 7 holders — while 374 added to existing stakes and 281 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $280M. The largest seller was Fidelity Investments, cutting an estimated $668M.
- 904 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2020, down from 907 in Q3 2020.
- Funds reported $43.6B of Regeneron Pharmaceuticals stock for Q4 2020, down 15% quarter-over-quarter.
- 142 funds opened new Regeneron Pharmaceuticals positions in Q4 2020 and 135 closed out, a net change of +7 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2020 was Susquehanna International Group, an estimated $280M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2020 was Fidelity Investments, an estimated $668M sold.
Based on aggregated 13F filings for Q4 2020.